In recent years, we have seen transformational advances in oncology treatment thanks to the arrival of immune checkpoint inhibitors.

Recent R&D focus on studying the benefits of combination therapies has stocked the pipeline full of multi-arm, multi-cohort and other novel Phase I/II trial designs.

This exciting time in oncology innovation has also brought challenges for strategists and planners – how can you stay on top of this ever-changing space and plan for future success?

Our oncology team has created this quick infographic to help clients plan strategies to win in this space and stay on top of competitor moves.

Download PDF



Fill out the form below to read our latest Executive Brief "How Can Pharma Find Success in the Evolving Immune Checkpoint Inhibitor Pipeline":


DRG becomes Clarivate

View Now